Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (934)	6/22/2001 12:47:51 PM
From: jayhawk969	Read Replies (1) \| Respond to of 1475

The PDLI news this morning will not hurt if the report is good. I have slowly added to my stake in this company. It is now one of my 5 core biotech holdings. A total market cap of 87 million, a very reasonable burn and a demonstrated potential to raise additional capital. As part of a basket, I agree with Rick, this one has a large x potential.

To: Icebrg who wrote (934)	6/25/2001 10:50:06 AM
From: Icebrg	Read Replies (1) \| Respond to of 1475

Robbie Stephens commenting on MEDI-507. "MedImmune, Inc. [NASDAQ: MEDI $45.30] Buy Michael King, Biopharmaceuticals Eric Shen, Biopharmaceuticals "Phase I/II trials results for MEDI-507 showed encouraging signs of therapeutic benefit," said King and Shen. "Even at very low doses, the drug showed encouraging activity, as measured by the gold-standard PASI 75 score. At high doses, MEDI-507 produced PASI 75 responses in roughly one-third of patients in a pooled data set, within the same range as more advanced drug candidates. While these results were in line with our expectations, we believe they come as an upside surprise to the Street. We reiterate our Buy rating on MEDI shares with a price target of $57."" robertsonstephens.com